Skip to main content


Details of the Drug
Generic Name:
Drug Type:
BCL-2 inhibitor
How the Drug is Given:

By Mouth


Indications and Usage

Venetoclax is FDA approved 

  • For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). 
  • In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.


Side effects needing medical attention

Neutropenia, diarrhea, nausea, anemia, upper respiratory tract infection, thrombocytopenia, and fatigue. Serious adverse reactions were pneumonia, febrile neutropenia, pyrexia (fever), autoimmune hemolytic anemia, anemia, and tumor lysis syndrome (TLS). 

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.